Head-to-head · free

Novartis AG vs Ovid Therapeutics Inc.

NVS vs OVID — return on capital, cash generation, margins and balance sheet side by side.

NVS

2 / 3

measures where NVS leads

OVID

1 / 3

measures where OVID leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureNVSOVID · FY2025
Revenue—$7.3M
Net income—(17.4M)
Revenue growth (yearly, multi-year)—-68.1%
Free cash flow—(38.3M)
Free cash flow margin—-528.6%
Net cash / (debt)——
ROIC18.6%—
Return on equity31.0%-17.5%
Gross margin75.8%—
Operating margin31.1%-585.2%
Net debt / EBITDA0.96x0.31x

Figures are as reported by each company; latest fiscal year shown.

Where Novartis AG's cash went

Not reported yet.

Full NVS profile →

Where Ovid Therapeutics Inc.'s cash went (FY2025)

Capital spending
$0
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full OVID profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons